What can be achieved with interferon therapy in chronic hepatitis?;WAS BRINGT DIE INTERFERONTHERAPIE BEI DER CHRONISCHEN HEPATITIS?

Internist

Volumn 38, Issue 12, 1997, Pages 1191-1203

  Boker K H W ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; RECOMBINANT INTERFERON;

ACUTE HEPATITIS; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS D, CHRONIC; HUMANS; INTERFERONS; PROGNOSIS; TREATMENT OUTCOME;

EID: 15144354408     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050131     Document Type: Review

References (77)

1. DiBisceglie AM, Hoofnagle JH (1996) Chronic viral Hepatitis, in Hepatology, edited by Zakim D, Boyer TD, Saunders, pp 1299-1328
2. Alter MJ (1995) Epidemiology of Hepatitis C in the West. Seminars in Liver disease. 15:5-14
3. Powell DW, Abramson BZ, Balint JA et al. (1997) Management of Hepatitis C. NIH Consensus Development Statement (1997). Hepatology 26:[Suppl 1] 2-155
4. Fleig W et al. (1997) Konsensus Konferenz über chronische Leberkrankheiten. Z Gastroenterologie, in press
5. Dianzani F (1993) Biological basis for the clinical use of Interferon. Gut 34:[Suppl2] S74-76
6. Jacobsen H (1990) Struktur und Wirkung von Interferonen, In: Interferone. Präklinische und klinische Befunde, edited by Niederle N, v. Wussow P, Berlin, Springer Verlag, pp 1-44
7. Milella M, Antonelli G, Santantonio T, et al. (1993) Neutralizing antibodies to recombinant alpha-inferferon and response to therapy in chronic hepatitis C virus infection. Liver 13:146-150
8. Bonetti P, Diodati G, Drago C et al. (1994) Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 20:416-420
9. Antonelli G, Currenti M, Turriziani O, et al. (1991) Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 163:882-885
10. Milella M, Antonelli G, Santantonio T, et al. (1995) Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 42:201-204
11. Ilan Y, Nagler A, Adler R, et al. (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104:1818-1821
12. Katkov WN, Dienstag JL (1991) Prevention and therapy of viral hepatitis. Semin Liver Dis 11:165-174
13. Rehermann B, Lau D, Hoofnagle JH et al. (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665
14. Korenman J, Baker B, Waggoner J et al. (1991) Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114:629-634
15. Niederau C, Heintges T, Lange S et al. (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422-1427
16. Greenberg HB, Pollard RB, Lutwick LI et al. (1976) Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:517-522
17. Tine F, Magrin S, Craxi A et al. (1991) Interferon for non-A, non-B chronic hepatitis. A metaanalysis of randomised clinical trials. J Hepatol 13:192-199
18. Krogsgard K, Bindslev N, Christensen E, et al. (1994) The treatment effect of alpha interferon in chronic hepatitis B is independent of pre treatment variables. (EUROHEP) J Hepatol 21:646-655
19. Wong DK, Cheung AM, O'Rourke K et al. (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323
20. Wong JB, Koff RS, Tine F et al. (1995) Costeffectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 122:664-675
21. Dusheiko GM, Roberts JA (1995) Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal [see comments].Hepatology 22:1863-1873
22. Carreno V, Castillo I, Molina J et al. (1992) Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 15:102-106
23. Lok AS, Chung HT, Liu VW et al. (1993) Longterm follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105:1833-1838
24. Realdi G, Fattovich G, Hadziyannis S et al. (1994) Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21:656-666
25. Koff RS, Seeff LB (1995) Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: promises and limitations. Hepatology 22:1880-1882
26. Chen G, Karayiannis P, McGarvey MJ et al. (1989) Subclasses of antibodies to hepatitis B core antigen in chronic HBV infection: changes during treatment with alpha interferons and predictors of response. Gut 30:1123-1128
27. Perrillo RP (1990) Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 12:1433-1435
28. Brook MG, Karayiannis P, Thomas HC (1989) Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10:761-763
29. Tassopoulos N, Hadzyannis SJ, Wright GE (1989) A randomized double blind placebo controlled trial of alfa interferon in acute type B Hepatitis. Hepatology 10:575
30. Halevy J, Achiron A, Spiegel D et al. (1990) Recombinant alpha-interferon may be efficacious in acute hepatitis B. Am J Gastroenterol 85:210-212
31. Brunetto MR, Oliveri F, Rocca G et al. (1989) Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10:198-202
32. Fattovich G, Farci P, Rugge M et al. (1992) A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15:584-589
33. Sureau C, Moriarty AM, Thornton GB et al. (1992) Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens. J Virol 66:1241-1245
34. Rizzetto M, Ponzetto A, Bonino F et al. (1986) Superimposed hepatitis and the effect on viral replication in chronic hepatitis B. J Hepatol
35. Malaguarnera M, Restuccia S, Pistone G et al. (1996) A meta-analysis of interferon-alpha treatment of hepatitis D virus infection. Pharmacotherapy 16:609-614
36. Gaudin JL, Faure P, Godinot H et al. (1995) The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 15:45-52
37. Farci P, Mandas A, Coiania A et al. (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330:88-94
38. Madejon A, Cotonat T, Bartolome J et al. (1994) Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 19:1331-1336
39. Rosina F, Pintus C, Meschievitz C et al. (1991) A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 13:1052-1056
40. Rosina F, Cozzolongo R (1994) Interferon in HDV infection. Antiviral Res 24:165-174
41. Lau JY, King R, Tibbs CJ et al. (1993) Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol 39:292-296
42. Alter MJ, Margolis HS, Krawczynski K et al. (1992) The natural history of community-acquired hepatitis C in the United States.The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 327:1899-1905
43. Seeff LB, Buskell BZ, Wright EC et al. (1992) Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group [see comments]. N Engl J Med 327:1906-1911
44. Tong MJ, el FN, Reikes AR et al. (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466
45. Dienstag JL (1997) The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 112:651-655
46. Terrault N, Wright T (1995) Interferon and hepatitis C virus infection. N Engl J Med 332:1509-1511
47. Davis GL, Balart LA, Schiff ER et al. (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321(22):1501-1506
48. Di Bisceglie AM, Martin P, Kassianides C et al. (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510
49. Poynard T, Leroy V, Cohard M et al. (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24:778-789
50. Chemello L, Bonetti P, Cavalletto L et al. (1995) Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 22:700-706
51. Shiratori Y, Kato N, Yokosuka O et al. (1997) Predictors of the Efficacy of Interferon Therapy in Chronic Hepatitis C Virus Infection. Gastroenterology 113:558-566
52. Saracco G, Rizzetto M (1996) Predictors of response to interferon therapy. Dig Dis Sci
53. Martinot PM, Marcellin P, Pouteau M et al. (1995) Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology
54. Chemello L, Cavalletto L, Noventa F et al. (1995) Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat 2:91-96
55. Conjeevaram HS, Everhart JE, Hoofnagle JH (1995) Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology
56. Trepo C, Bailly F (1996) Magnitude and management of HCV infection in France. Dig Dis Sci
57. Camma C, Almasio P, Craxi A (1996) Interferon as treatment for acute Hepatitis C. Dig Dis Sci 41:1248-1255
58. Vogel W, Graziadei I, Umlauft F et al. (1996) High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 41:[Suppl 12] p 81-85
59. Fattovich G, Giustina G, Favarato S et al. (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38-47
60. Soriano V, Bravo R, Samaniego JG et al. (1994) CD4+T-Lymphozytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. AIDS 8:1621-1622
61. Shakil AO, Di BA, Hoofnagle JH (1996) Seizures during alpha interferon therapy. J Hepatol 24:48-51
62. Janssen HL, Schalm SW, Berk L et al. (1993) Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 17:[Suppl 3] S 47-51
63. Arase Y, Kumada H, Chayama K et al. (1994) Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C. J Gastroenterol 29:299-304
64. Rabinovitz M, Block G, Finkelstein SD (1996) Alpha-Interferon retreatment of patients with chronic hepatitis C. Am J Gastroenterol 91:1523-1526
65. Pol S, Thiers V, Carnot F et al. (1995) Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47:1412-1418
66. Gilbert RD, Wiggelinkhuizen J (1994) The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 8:11-14
67. Gordon SC (1996) Extrahepatic manifestations of hepatitis C. Dig Dis 14:157-168
68. Shapiro RJ, Steinbrecher UP, Magil A (1995) Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol 15:343-347
69. Ferri C, Marzo E, Longombardo G et al. (1993) Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81:1132-1136
70. Komatsuda A, Imai H, Wakui H et al. (1996) Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med 35:529-533
71. Lai KN,Li PK, Lui SF et al. (1991) Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324(21):1457-1463
72. Todo S, Demetris AJ, Van TD et al. (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13:619-626
73. Feray C, Samuel D, Gigou M et al. (1995) An open trial of Interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 22:1084-1089
74. Singh N, Gayowski T, Wannstedt CF et al. (1996) Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 10:348-351
75. Nishiguchi S, Kuroki T, Nakatani S et al. (1995) Randomised trial of effects of Interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346(8982):1051-1055
76. Mazzella G, Accogli E, Sottili S et al. (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141-147
77. Rockey DC, Maher JJ, Jarnagin WR et al. (1992) Inhibition of rat hepatic lipocyte activation In culture by interferon-gamma. Hepatology 16:776-784